Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Conversely, influenza vaccine was associated with increased COVID-19 severity and hospitalizations in patients with inflammatory rheumatic diseases.

Pneumococcal Vaccine Associated With Reduced COVID-19 Severity, Hospitalizations

Bristol Myers Squibb's deucravacitinib shows promise as a safe, effective treatment for active psoriatic arthritis, pending FDA approval by March 2026.

TYK2 Inhibitor Deucravacitinib up for FDA Review for Psoriatic Arthritis

Findings suggest clinical risk factors involved in the development of psoriatic arthritis in children with psoriasis, including BMI and psoriasis location.

Obesity, Nail Psoriasis May Increase Psoriatic Arthritis Risk in Children with Psoriasis

TYK2 inhibition may offer a potentially better tolerated treatment option than JAK inhibitors for people with PsA.

Zasocitinib Data Demonstrates Efficacy of TYK2 Inhibition for Psoriatic Arthritis

Explore groundbreaking FDA approvals and clinical trial advancements in rheumatology, offering new hope for patients with rare autoimmune diseases and chronic conditions.

H1 2025 Recap: 7 Rheumatology Updates to Know

The rheumatology month in review emphasizes new research in RA burden, fibromyalgia treatment, and insights from the EULAR 2025 meeting.

Rheumatology Month in Review: June 2025

Mease outlined positive efficacy and safety findings from multiple long-term follow-up trials of the biologic in people with PsA and AxSpA.

Bimekizumab Demonstrates Long-Term Benefit for Arthritis Post-Approval, with Philip Mease, MD

Presented at SDPA, the FOREMOST Trial showed apremilast reduces joint burden and improves function in early oligo PsA through week 48.


Apremilast Shows Long-Term Benefit in Early Oligoarticular Psoriatic Arthritis

Depressive symptoms in the first 2 years after diagnosis were linked to lower odds of achieving remission in both RA and PsA.

Depression Reduces Remission Likelihood in Rheumatoid, Psoriatic Arthritis

New Phase 3 trial results reveal deucravacitinib's effectiveness in treating active psoriatic arthritis, offering hope for improved patient outcomes.

Phase 3 Deucravacitinib Trial Meets ACR20 End Point in PsA

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.